𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pharmacoclinical data on high dose medroxyprogesterone acetate in advanced breast cancer

✍ Scribed by Moise Namer; Gérard Milano; Roger Khater; Marc Frenay; Antoine Thyss; Nicole Renée

Publisher
Springer US
Year
1986
Tongue
English
Weight
228 KB
Volume
8
Category
Article
ISSN
0167-6806

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of high-dose medroxypro
A phase II study of high-dose medroxyprogesterone acetate in advanced breast cancer
✍ Geoffrey Falkson; Hèndré C. Falkson 📂 Article 📅 1983 🏛 Springer 🌐 English ⚖ 215 KB

Twenty-three evaluable patients with advanced breast cancer were treated with MPA, 1,400 mg/m2 daily PO for the first 6 months, and 500 mg/m2 daily PO thereafter. The median total dose was 191,400 mg in 88 days, with the maximum dose given to date 522,600 mg in 282 days. Most patients tolerated high

Medroxyprogesterone acetate bioavailabil
Medroxyprogesterone acetate bioavailability after high-dose intraperitoneal administration in advanced cancer
✍ Carlo M. Camaggi; Elena Strocchi; Barbara Costanti; Paola Beghelli; Patrizio Fer 📂 Article 📅 1985 🏛 Springer 🌐 English ⚖ 273 KB

Administration of medroxyprogesterone acetate IP in advanced cancer with peritoneal metastases and ascitic effusion generates considerably higher drug plasma levels than those observed after PO or IM treatment. Comparison of areas under the time-concentration curves (AUC) with reference to the three